- Home
- THRD
as 02-21-2025 4:00pm EST
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 335.2M | IPO Year: | 2022 |
| Target Price: | $14.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.18 - $16.94 | Next Earning Date: | 03-25-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Third Harmonic Bio Inc. News
THRD Breaking Stock News: Dive into THRD Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
9 days ago
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
Benzinga
10 days ago
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
MT Newswires
11 days ago
Morgan Stanley Downgrades Third Harmonic Bio to Equal Weight From Overweight, Adjusts Price Target to $5 From $20
MT Newswires
11 days ago
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20
MT Newswires
12 days ago
Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set
GlobeNewswire
12 days ago
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
BioPharma Dive
12 days ago
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
Compare THRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THRD Third Harmonic Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.